(MNTA)—CHRS halts development on Humira FoB for time being due to IPR loss on ABBV’s ‘619 formulation patent (#msg-134452711). This was confirmed on CHRS’ 3Q17 CC this afternoon.
CHRS’ new guidance for the timing its Humira-FoB US launch is late 2022—i.e. around the time of AMGN’s Jan 2023 guaranteed launch date in AMGN’s recent litigation settlement with ABBV (#msg-134970085).
MNTA too is backing off its prior assertion of being able to circumvent ABBV’s Humira-formulation patents and hinted on its own 3Q17 CC last week that the US launch of M923 probably won’t happen until 2022.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.